报价延迟最少15分钟:2026/08/04 05:14 EDT
盘前时段
|
||||
|
19.5 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.35/-3.06
|
|
企业价值
2.14B
|
| 资产负债 |
|
每股账面净值
4.56
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
70.85M
|
|
每股收益
0.01
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibodytargeting IGF-1R intravenously administered for the treatment of TED. |
